Abstract | BACKGROUND: The effect of preemptive therapy on indirect sequelae associated with cytomegalovirus (CMV) in liver-transplant recipients has not been clearly delineated. METHODS: Thirteen years of outcome with the use of preemptive therapy were assessed in a cohort of 216 consecutive liver-transplant recipients. RESULTS: CONCLUSIONS:
Liver-transplant recipients with CMV infection, including high-risk R-/D+ patients, when followed using the preemptive therapy approach had no significant difference in meaningful outcomes such as opportunistic superinfections, HCV recurrence rates, rejection, and survival when compared with the patients in whom CMV infection never developed and who did not receive antiviral prophylaxis for CMV.
|
Authors | Nina Singh, Cheryl Wannstedt, Lois Keyes, Marilyn M Wagener, Timothy Gayowski, Thomas V Cacciarelli |
Journal | Transplantation
(Transplantation)
Vol. 79
Issue 10
Pg. 1428-34
(May 27 2005)
ISSN: 0041-1337 [Print] United States |
PMID | 15912115
(Publication Type: Journal Article)
|
Chemical References |
- Antiviral Agents
- Ganciclovir
- Acyclovir
|
Topics |
- Acyclovir
(therapeutic use)
- Adult
- Aged
- Antiviral Agents
(therapeutic use)
- Cytomegalovirus Infections
(prevention & control)
- Female
- Ganciclovir
(therapeutic use)
- Hepatitis C
(epidemiology)
- Humans
- Incidence
- Liver Transplantation
(mortality, statistics & numerical data)
- Longitudinal Studies
- Male
- Middle Aged
- Opportunistic Infections
(epidemiology)
- Recurrence
- Survival Analysis
- Viremia
(drug therapy)
|